McCool KW, et al. - Among women receiving neoadjuvant chemotherapy for ovarian cancer, researchers evaluated the prevalence and oncologic safety of perioperative allogeneic blood transfusion during interval cytoreduction surgery. Outcomes were compared in patients who were exposed to perioperative blood transfusion vs patients who were not. Findings suggested a high risk of exposure to blood transfusion at the time of interval cytoreductive surgery in women undergoing neoadjuvant chemotherapy for ovarian cancer. In the transfusion group, the preoperative hemoglobin concentration was lower. They did not note an association of perioperative transfusion with a significant difference in progression-free survival (PFS = 7.6 months for transfused, 9.4 months for not transfused; log-rank test).